- Home
- BOLT vs SABS Comparison
BOLT vs SABS Comparison
Compare BOLT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- SABS
- Stock Information
- Founded
- BOLT 2015
- SABS 2014
- Country
- BOLT United States
- SABS United States
- Employees
- BOLT N/A
- SABS N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- SABS Health Care
- Exchange
- BOLT Nasdaq
- SABS Nasdaq
- Market Cap
- BOLT 22.6M
- SABS 19.0M
- IPO Year
- BOLT 2021
- SABS N/A
- Fundamental
- Price
- BOLT $0.49
- SABS $1.82
- Analyst Decision
- BOLT Hold
- SABS Strong Buy
- Analyst Count
- BOLT 5
- SABS 5
- Target Price
- BOLT $1.25
- SABS $12.40
- AVG Volume (30 Days)
- BOLT 114.3K
- SABS 246.2K
- Earning Date
- BOLT 03-20-2025
- SABS 03-28-2025
- Dividend Yield
- BOLT N/A
- SABS N/A
- EPS Growth
- BOLT N/A
- SABS N/A
- EPS
- BOLT N/A
- SABS N/A
- Revenue
- BOLT $9,779,000.00
- SABS $1,512,723.00
- Revenue This Year
- BOLT $9.87
- SABS N/A
- Revenue Next Year
- BOLT N/A
- SABS N/A
- P/E Ratio
- BOLT N/A
- SABS N/A
- Revenue Growth
- BOLT 35.86
- SABS N/A
- 52 Week Low
- BOLT $0.46
- SABS $1.60
- 52 Week High
- BOLT $1.56
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- BOLT 45.52
- SABS 36.28
- Support Level
- BOLT $0.48
- SABS $2.00
- Resistance Level
- BOLT $0.52
- SABS $2.15
- Average True Range (ATR)
- BOLT 0.03
- SABS 0.20
- MACD
- BOLT 0.00
- SABS 0.03
- Stochastic Oscillator
- BOLT 40.32
- SABS 30.99
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.